OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. McDermott on TKI/Immunotherapy Combinations in RCC

November 12th 2019

David F. McDermott, MD, discusses the combination of VEGF TKIs and PD-1 inhibitors in advanced renal cell carcinoma.

Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLC

November 12th 2019

Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.

Dr. Somer on Lowering the Cost of Cancer Care With Biosimilars

November 12th 2019

Bradley G. Somer, MD, discusses lowering the cost of cancer care with biosimilars.

Dr. Essel on Rationale to Explore Quantitative CT Image Feature Analysis in Gynecologic Cancers

November 9th 2019

Kathleen G. Essel, MD, discusses the rationale to explore quantitative computed tomography image feature analysis in gynecologic cancers.

Dr. Tauer on Arguments in Favor of and Against Biosimilars in Oncology

November 9th 2019

Kurt Tauer, MD, FACP, discusses arguments in favor of and against biosimilars in oncology.

Dr. Lai on the Results of the CASPIAN Trial in Small Cell Lung Cancer

November 9th 2019

W. Victoria Lai, MD, discusses the results of the phase III CASPIAN trial in small cell lung cancer.

Potential of Genetic Testing Beyond BRCA1/2 in Ovarian Cancer

November 9th 2019

Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

Dr. Polsky on Potential Applications of ctDNA in Melanoma

November 9th 2019

David Polsky, MD, PhD, discusses potential applications of circulating tumor DNA as a biomarker in melanoma.

Dr. O'Regan on Prognostic Value of pCR in HER2+ Breast Cancer

November 9th 2019

Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.

Dr. Oh on Choosing AR-Targeted Therapy Versus Chemotherapy in mHSPC

November 8th 2019

William K. Oh, MD, discusses factors to consider when choosing a treatment for patients with metastatic hormone-sensitive prostate cancer.

Dr. Al-Sawaf on Testing for CKT in CLL

November 8th 2019

Othman Al-Sawaf, MD, discusses checking complex karyotype in patients with chronic lymphocytic leukemia.

Dr. Jhaveri on the Use of Trastuzumab Biosimilars in Breast Cancer

November 8th 2019

Komal Jhaveri, MD, FACP, discusses the use of trastuzumab biosimilars in breast cancer.

Dr. Brufsky on Challenges in Breast Cancer Treatment

November 8th 2019

Adam M. Brufsky, MD, PhD, discusses remaining challenges in breast cancer.

Dr. Luke on Treatment Options in Metastatic Melanoma

November 8th 2019

Jason J. Luke, MD, FACP, discusses the treatment landscape of metastatic melanoma.

Dr. Coleman on Investigational Treatment Strategies in Cervical Cancer

November 8th 2019

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses investigational treatment strategies in cervical cancer.

Dr. Backes on Treatment Selection With PARP Inhibitors in Ovarian Cancer

November 8th 2019

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses treatment selection with PARP inhibitors in ovarian cancer.

Dr. Daud on Interferon Gamma as a Biomarker in Melanoma

November 8th 2019

Adil Daud, MD, clinical professor, Department of Medicine (Hematology/Oncology) and director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses research evaluating interferon gamma as a potential biomarker of response in melanoma.

Dr. Furman on Prognostic Markers in High-Risk CLL

November 7th 2019

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

Dr. Motzer on First-Line Treatment of Metastatic RCC

November 7th 2019

Robert J. Motzer, MD, discusses the first-line treatment landscape of metastatic clear cell renal cell carcinoma.

Dr. Waxman on the Future of Treatment in Multiple Myeloma

November 7th 2019

Adam J. Waxman, MD, MS, assistant professor of clinical medicine, Penn Medicine, University of Pennsylvania, discusses the future of treatment in patients with multiple myeloma.